Company profile: ChromaCode
1.1 - Company Overview
Company description
- Provider of HDPCR-based molecular diagnostics and bioinformatics solutions for tumor profiling, minimal residual disease detection, and decentralized disease monitoring, paired with cloud software for automated interpretation, remote analysis, and scalable deployment; offerings include a multiplexed NSCLC panel delivering results in 24 hours with high concordance to NGS.
Products and services
- HDPCR + ChromaCode Cloud: Cloud-based platform combines HDPCR with automated interpretation of multiplexed assays, facilitating remote analysis and scalable deployment
- HDPCR for Tumor Profiling: Comprehensive HDPCR-based system profiles DNA and RNA variants in tumors, offering a simpler alternative to NGS with rapid results
- HDPCR for Minimal Residual Disease (MRD): Sensitive HDPCR assays deliver rapid detection of minimal residual disease, offering a cost-effective alternative to NGS
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ChromaCode
BridgeBio Pharma
HQ: United States
Website
- Description: Provider of precision medicines for genetic diseases and cancers, developing assets including BBP-398 (SHP2 inhibitor for MAPK/RAS-driven cancers), BBP-631 (AAV5 gene therapy for congenital adrenal hyperplasia), BBP-818 (AAV gene therapy for classic galactosemia), BBP-589 (recombinant collagen 7 for dystrophic epidermolysis bullosa), BBP-681 (topical PI3KA inhibitor), and BBP-711 (GO inhibitor).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BridgeBio Pharma company profile →
Guide Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions addressing delivery of genetic therapies, leveraging patented technologies to test thousands of chemically distinct nanoparticles in vivo to identify simple, scalable, clinically relevant nanoparticles that target new cell types efficiently and safely.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Guide Therapeutics company profile →
Astute Medical
HQ: United States
Website
- Description: Provider of diagnostic solutions for high-risk medical conditions via identification and validation of protein biomarkers, focused on community and hospital-acquired acute conditions needing rapid diagnosis and risk assessment. Products include BIOFIRE FILMARRAY Torch, VITEK MS, VIDAS BRAHMS PCT, and BACT/ALERT VIRTUO.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Astute Medical company profile →
MeiraGTx
HQ: United States
Website
- Description: Provider of AAV-based gene therapies for inherited and acquired disorders, including programs for X-linked retinitis pigmentosa (RPGR), RPE65-associated retinal dystrophy, achromatopsia (CNGB3 and CNGA3), radiation-induced xerostomia (AAV2-hAQP1), and Parkinson’s disease (AAV-GAD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MeiraGTx company profile →
NYtor
HQ: The Netherlands
Website
- Description: Provider of biotechnology research solutions, offering quantitative PCR, molecular beacons, and antibiotic resistance services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NYtor company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ChromaCode
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ChromaCode
2.2 - Growth funds investing in similar companies to ChromaCode
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ChromaCode
4.2 - Public trading comparable groups for ChromaCode
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →